comparemela.com
Home
Live Updates
Abatacept Gets Priority Review for Moderate to Severe Acute Graft Versus Host Disease : comparemela.com
Abatacept Gets Priority Review for Moderate to Severe Acute Graft Versus Host Disease
Abatacept (Orencia) is under review for the prevention of moderate to severe acute graft versus host disease in patients 6 years of age and older.
Related Keywords
Boston ,
Massachusetts ,
United States ,
Leslie Kean ,
Drug Administration ,
Pediatric Stem Cell Transplantation Program ,
Boston Children Hospital Dana Farber Cancer Institute ,
Priority Review ,
Biologics License Application ,
Prescription Drug User Fee Act ,
Boston Children ,
Dana Farber Cancer ,
comparemela.com © 2020. All Rights Reserved.